Paul Zolkind

Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial

Ravindra Uppaluri, Katie M. Campbell, Ann Marie Egloff et al. · Clinical Cancer Research · 2020 · 365 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen–Specific T Cells

Jay Friedman, Ellen Moore, Paul Zolkind et al. · Clinical Cancer Research · 2019 · 85 citations · Full text

Life Sciences, Immunology, Oncology +17

Neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV negative head and neck squamous cell carcinoma (HNSCC).

Ravindra Uppaluri, Paul Zolkind, Tianxiang Lin et al. · Journal of Clinical Oncology · 2017 · 77 citations

Medicine, Oncology, Radiation Oncology +16

Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window-of-Opportunity Clinical Trial

Ravindra Uppaluri, Ashley E. Winkler, Tianxiang Lin et al. · Clinical Cancer Research · 2016 · 53 citations · Full text

Medicine, Oncology, Pharmacology +16

Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders

Liye Zhou, Zexian Zeng, Ann Marie Egloff et al. · Journal for ImmunoTherapy of Cancer · 2022 · 51 citations · Full text

Medicine, Immunology, Oncology +17